Modern blood cancer treatments require new approach for monitoring, reporting side effects

June 13, 2018, Lancet

Treatment changes including the advent of targeted and immune therapies have dramatically improved survival for blood cancers, but new report calls for improved evaluation of poorly understood side effects that may develop over time.—-

Survival rates for blood cancers—including lymphoma, myeloma and some types of leukaemia—have dramatically increased over the past decade, due in great part to novel treatment approaches including molecularly-targeted therapies and immunotherapies.

In contrast to traditional forms of treatment which were largely episodic and finite (ie, a set number of cycles of intravenous chemotherapy), for some haematological cancers may now be given continuously over years, or in some cases indefinitely.

However, a new Commission by The Lancet Haematology shows how current methods of reporting adverse events, focused on assessing a drug or regimen's safety, often fail to also appropriately identify important delayed, chronic or cumulative effects that can affect substantially.

In particular, the toxicity over time and tolerability to the patient of new chronic or continuously administered therapies are not well defined, and are poorly captured by existing reporting mechanisms.

The Commission brings together 40 leading clinicians, clinical investigators, regulators, biostatisticians and patient advocates to analyse the evidence and propose recommendations to policy makers, researchers, industry and regulators, and will be launched at the European Haematological Association meeting in Stockholm.

"The success in outcomes and survival in many haematological malignancies is historically unparalleled and fuelled by scientific discovery and implementation. Patients are now living with the challenge of managing not just their haematological malignancy, but also managing chronic therapy for their illness, with new types of acute, chronic, cumulative and late toxicities. Measures to address the broad facets of toxicity assessment must be prioritised and further developed to ultimately enhance accurate, comprehensive, patient-centred toxicity reporting that will meaningfully inform the care of patients with ," says Commission Chair Dr. Gita Thanarajasingam, Mayo Clinic, Rochester (MN).

The authors propose new approaches to evaluating and reporting adverse events to complement the current methods. These include expanding reporting beyond high grade, acute toxic side-effects, and capturing less severe but chronic side effects, and cumulative and late effects in a more standardized manner. While short term side effects with some regimens might include nausea and vomiting occurring over a few days in a cycle, long term effects might include neuropathy which worsens over time with ongoing drug exposure and can persist even after therapy is complete, for example.

Additionally, the authors emphasize that changes to clinical trial design to accommodate delayed adverse events, and incorporating patient reported outcomes into trials to assess and improve tolerability, adherence and quality of life are essential.

The Commission also examines streamlined approaches to identify unexpected side effects from stem cell transplantation and improved evaluation of late and long term side effects in survivors. As newer treatments in haematological malignancies are offered more widely, capturing data from population studies will be essential to understand side effects outside of clinical trial settings. Additionally, post-marketing surveillance by regulatory agencies should adapt to include relevant data on long-term in a real world patient population.

Explore further: Reporting of adverse events in targeted therapy and immunotherapy trials is 'suboptimal'

More information: The Lancet Haematology, www.thelancet.com/journals/lan … (18)30051-6/fulltext

Related Stories

Reporting of adverse events in targeted therapy and immunotherapy trials is 'suboptimal'

October 5, 2016
A significant number of trials of targeted therapies and immunotherapies in recent years show suboptimal reporting of adverse events, particularly the reporting of recurrent or late toxicities and the duration of the adverse ...

Evaluating pediatric leukemia treatment

April 12, 2018
A drug called dasatinib was found to be safe and effective for children with chronic myeloid leukemia, according to a clinical trial published in the Journal of Clinical Oncology.

Trial confirms pelvic radiation as standard of care for high-risk endometrial cancer

September 25, 2017
In a new phase III trial report from the National Clinical Trial Network group, NRG Oncology, recurrence-free and overall survival rates for women with stage I-II high-risk endometrial cancer were not superior following vaginal ...

Combined therapies increase side effects for patients with advanced breast cancer

November 2, 2017
Lisbon, Portugal: Patients with advanced breast cancer who are treated with a combination of drugs that target specific molecules important for cancer development and also the hormones that are driving it are at increased ...

Halving radiation therapy for HPV-related throat cancer offers fewer side effects, similar outcomes

September 25, 2017
Mayo Clinic researchers have found that a 50 percent reduction in the intensity and dose of radiation therapy for patients with HPV-related throat cancer reduced side effects with no loss in survival and no decrease in cure ...

Measuring patients' muscles to predict chemotherapy side effects

February 22, 2017
Chemotherapy has long been standard treatment for many cancers, but its clinical benefits can also come with well-documented side effects. Doctors say the challenge is knowing which patients will experience these side effects, ...

Recommended for you

Novel therapy makes oxidative stress deadly to cancer

June 21, 2018
Oxidative stress can help tumors thrive, but one way novel cancer treatments work is by pushing levels to the point where it instead helps them die, scientists report.

Biologists discover how pancreatic tumors lead to weight loss

June 20, 2018
Patients with pancreatic cancer usually experience significant weight loss, which can begin very early in the disease. A new study from MIT and Dana-Farber Cancer Institute offers insight into how this happens, and suggests ...

Researchers find 11 genes responsible for the spread of cancer

June 20, 2018
A groundbreaking discovery by University of Alberta researchers has identified previously-unknown therapeutic targets that could be key to preventing the spread of cancer.

'Kiss of death' cancer: How computational geeks may have uncovered a therapy for a deadly disease

June 19, 2018
It's called the 'kiss of death'. Triple negative breast cancer has no targeted drug therapy and, as such, the only hope for these patients is chemotherapy. Triple negative breast cancer is aggressive and deadly. Patients ...

Ovarian cancer cells switched off by 'unusual' mechanism

June 19, 2018
Scientists at the Ovarian Cancer Action Research Centre at Imperial College London have discovered a mechanism that deactivates ovarian cancer cells.

Team discovers gene mutations linked to pancreatic cancer

June 19, 2018
Six genes contain mutations that may be passed down in families, substantially increasing a person's risk for pancreatic cancer. That's according to Mayo Clinic research published in the June 19 edition of the JAMA. However, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.